Loading...
OTCMBDPT
Market cap425kUSD
Dec 26, Last price  
0.10USD
1D
15.31%
1Q
14,725.00%
Jan 2017
-50.58%
IPO
-97.16%
Name

BioAdaptives Inc

Chart & Performance

D1W1MN
OTCM:BDPT chart
P/E
—
P/S
14.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
101.16%
Rev. gr., 5y
%
Revenues
29k
+66.31%
00019,044009,93416,32719,77617,17628,565
Net income
-712k
L-34.04%
-17,780-2,575,433-227,432-171,348-62,499-1,406,663-438,246-1,077,572-1,322,342-1,080,119-712,466
CFO
-224k
L-1.53%
-26,047-58,628-7200-402,145-168,120-106,889-158,651-227,259-223,773

Profile

BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
URL
https://www.shopbioadaptives.com/
IPO date
Jul 09, 2014
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
29
66.31%
17
-13.15%
20
21.12%
Cost of revenue
229
377
522
Unusual Expense (Income)
NOPBT
(201)
(360)
(502)
NOPBT Margin
Operating Taxes
185
272
Tax Rate
NOPAT
(201)
(544)
(775)
Net income
(712)
-34.04%
(1,080)
-18.32%
(1,322)
22.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
178
522
857
BB yield
-63.71%
-820.16%
-253.87%
Debt
Debt current
329
392
437
Long-term debt
Deferred revenue
Other long-term liabilities
399
Net debt
268
367
354
Cash flow
Cash from operating activities
(224)
(227)
(159)
CAPEX
Cash from investing activities
148
254
Cash from financing activities
259
170
237
FCF
70
(198)
(955)
Balance
Cash
61
25
83
Long term investments
Excess cash
59
25
82
Stockholders' equity
(8,175)
(7,526)
(6,651)
Invested Capital
6,857
6,467
5,995
ROIC
ROCE
15.24%
33.96%
76.54%
EV
Common stock shares outstanding
559,069
106,011
33,743
Price
0.00
-16.67%
0.00
-94.00%
0.01
-58.33%
Market cap
280
339.47%
64
-81.15%
337
-31.04%
EV
548
430
691
EBITDA
(173)
(298)
(368)
EV/EBITDA
Interest
163
289
272
Interest/NOPBT